naltrexone has been researched along with Depression in 54 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (3.70) | 18.7374 |
1990's | 3 (5.56) | 18.2507 |
2000's | 18 (33.33) | 29.6817 |
2010's | 27 (50.00) | 24.3611 |
2020's | 4 (7.41) | 2.80 |
Authors | Studies |
---|---|
Choo, TH; Fishman, M; Lee, JD; Nunes, E; Pavlicova, M; Rotrosen, J; Vest, N; Wenzel, K | 1 |
Burke, NN; Deaver, DR; Eyerman, DJ; Finn, DP; Kelly, JP; Li, Y; Roche, M; Sanchez, C | 1 |
Browne, CA; Lucki, I; Smith, T | 1 |
Chen, J; Dombrovski, AY; Karim, HT; Karp, JF; Lyew, T; Mizuno, A; Peciña, M | 1 |
Anderson, PM; Hillhouse, TM; Kegen, TN; Koppenhaver, PO; Lane, JT; Manicka, SG; Porter, JH; Pottanat, E; Rice, R; Van Fossen, M; Zhang, F | 1 |
Bidlack, JM; Callaghan, CK; Dean, RL; Deaver, DR; Knapp, BI; O'Mara, SM; Rouine, J | 1 |
da Luz, SC; Nogueira, CW; Pesarico, AP; Rosa, SG; Tagliapietra, CF | 1 |
Carroll, KM; DeVito, EE; Frankforter, TL; Kiluk, BD; Nich, C; Sofuoglu, M; Yip, SW | 1 |
Cioe, PA; Kahler, CW; Lechner, WV; Sidhu, NK | 1 |
Hashimoto, K; Zhang, K | 1 |
Burke, NN; Deaver, DR; Ferdousi, M; Finn, DP; Kelly, JP; Roche, M | 1 |
Krajci, P; Kunoe, N; Latif, ZE; Opheim, A; Šaltyte Benth, J; Sharma-Haase, K; Solli, KK; Tanum, L | 1 |
Krystal, JH; Petrakis, IL; Yoon, G | 1 |
Bentzley, BS; Heifets, BD; Schatzberg, AF; Williams, NR | 1 |
Abdollahzadeh Estakhri, MR; Dehpour, AR; Haj-Mirzaian, A; Hamzeh, N; Javadi-Paydar, M | 1 |
Banks, ML; Bowers, MS; Carlezon, WA; Cheng, K; Leitl, MD; Negus, SS; Onvani, S; Rice, KC | 1 |
Dehpour, AR; Ejtemaei Mehr, S; Haj-Mirzaian, A; Kordjazy, N; Ostadhadi, S | 1 |
Falcon, E; Hill-Smith, TE; Lucki, I; Maier, K; Robinson, SA | 1 |
Booij, J; de Bruin, K; Goudriaan, AE; Koeter, MW; Lammers, LA; van den Brink, W; van Dijk, L; Zaaijer, ER | 1 |
Almatroudi, A; Bailey, CP; Bailey, SJ; Husbands, SM | 1 |
Adamson, SJ; Boden, JM; Foulds, JA; Mulder, RT; Newton-Howes, G; Sellman, JD | 1 |
Ficek, J; Golda, S; Korostynski, M; Piechota, M; Przewlocki, R; Szklarczyk, K | 1 |
Blokhina, E; Burakov, A; Bushara, N; Krupitsky, E; Masalov, D; Palatkin, V; Pecoraro, A; Romanova, T; Tsoy-Podosenin, M; Tyurina, A; Verbitskaya, E; Wahlgren, V; Woody, G; Yaroslavtseva, T; Zvartau, E | 1 |
Epstein, A; King, A; Munisamy, G; Walsh, Z | 1 |
Cooney, JL; Cooney, NL; McKee, SA; O'Malley, SS; Toll, BA | 1 |
Bucello, S; Cavarretta, R; Comi, G; Cursi, M; Franchi, S; Gironi, M; Martinelli, V; Martinelli-Boneschi, F; Martino, G; Moiola, L; Nemni, R; Pilato, V; Radaelli, M; Rodegher, M; Sacerdote, P; Solaro, C; Zaffaroni, M | 1 |
Meyer, F | 1 |
Gopalakrishnan, R; O'Brien, C; Oslin, D; Ross, J | 1 |
Gossop, M; Hegstad, S; Hjerkinn, B; Kristensen, Ø; Kunøe, N; Lobmaier, P; Vederhus, JK; Waal, H | 1 |
Cheng, WY; Mysels, DJ; Nunes, EV; Sullivan, MA | 1 |
Fujii, H; Nagase, H; Nemoto, T; Oka, J; Saitoh, A; Sugiyama, A; Wada, K; Yamada, M | 1 |
Carlezon, WA; Chartoff, E; Pliakas, A; Potter, D; Rachlin, A; Sawyer, A | 1 |
Jovanović, T; Lazarević, D; Nikolić, G | 1 |
Chen, Q; Lv, SY; Qin, YJ; Wang, HT; Xu, N; Yang, YJ | 1 |
Bailey, SJ; Casal-Dominguez, JJ; Clark, M; Husbands, SM; Traynor, JR | 1 |
Chen, J; Duman, RS; Nestler, EJ; Neve, R; Newton, SS; Sakai, N; Schlesinger, L; Shirayama, Y; Thome, J; Wallace, TL | 1 |
Helwig, H; Jahn, H; Kiefer, F; Otte, C; Tarnaske, T; Wiedemann, K | 1 |
Connor, JP; Dean, AJ; Jones, RT; Lawford, BR; Saunders, JB; Young, RM | 1 |
Deas, D; Dosh, T; Kazura, A; Kratochvil, CJ; Martin, CA; Wilens, TE | 1 |
Roesner, S; Soyka, M | 1 |
Capone, C; Farren, CK; Grilo, CM; McKee, SA; O'Malley, SS; Rounsaville, BJ; Sinha, R; Wu, R | 1 |
al'Absi, M; Bruehl, S; Burns, JW; Chung, OY; France, CR; France, J; Harju, A | 1 |
Drummond, PD; Frew, AK | 1 |
Bohus, B; Cottrell, GA; Nyakas, C | 1 |
Goldberg, G; Mantero-Atienza, E; Mason, BJ; Morgan, RO; Ritvo, EC; Salvato, FR; Welch, B | 1 |
Swift, RM | 1 |
Albano, SA; Wiley, DB; Zaim, S | 1 |
Befort, K; Chluba, J; Dierich, A; Filliol, D; Gavériaux-Ruff, C; Ghozland, S; Kieffer, BL; LeMeur, M; Maldonado, R; Martin, M; Matthes, HW; Simonin, F; Valverde, O | 1 |
Brandão, ML; Cuadra, G; Martijena, I; Molina, V; Zurita, A | 1 |
Bolm, T; Piegler, T | 1 |
Kranzler, HR; Van Kirk, J | 1 |
Basch, J; Ling, W; McCann, M; Miotto, K; Rawson, R | 1 |
Lewis, DC | 1 |
4 review(s) available for naltrexone and Depression
Article | Year |
---|---|
New pharmacological approaches for the treatment of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Carbamazepine; Depression; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Secondary Prevention; Taurine; Topiramate | 2006 |
The pharmacological treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depression; Disulfiram; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine | 1997 |
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Taurine; Treatment Outcome | 2001 |
Naltrexone and dysphoria: fact or myth?
Topics: Affect; Depression; Humans; Naltrexone; Narcotic Antagonists; Substance-Related Disorders | 2002 |
16 trial(s) available for naltrexone and Depression
Article | Year |
---|---|
Naltrexone modulates contextual processing in depression.
Topics: Cross-Over Studies; Depression; Double-Blind Method; Emotions; Facial Expression; Humans; Magnetic Resonance Imaging; Naltrexone | 2020 |
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder.
Topics: Administration, Oral; Adult; Anhedonia; Anxiety; Depression; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Dropouts; Treatment Outcome | 2018 |
Effects of time-varying changes in tobacco and alcohol use on depressive symptoms following pharmaco-behavioral treatment for smoking and heavy drinking.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy; Depression; Female; Humans; Male; Middle Aged; Naltrexone; Smoking Cessation; Time Factors; Tobacco Smoking; Tobacco Use Disorder | 2019 |
Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.
Topics: Administration, Oral; Adolescent; Adult; Anxiety; Buprenorphine, Naloxone Drug Combination; Comorbidity; Delayed-Action Preparations; Depression; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Opioid-Related Disorders; Sleep Initiation and Maintenance Disorders; Young Adult | 2019 |
Personality Predictors of Drinking Outcomes in Depressed Alcohol-Dependent Patients.
Topics: Adult; Alcoholism; Character; Citalopram; Depression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Personality Inventory; Prognosis; Temperament; Treatment Outcome; Young Adult | 2016 |
Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.
Topics: Administration, Oral; Adult; Anhedonia; Anxiety; Craving; Delayed-Action Preparations; Depression; Double-Blind Method; Drug Implants; Female; Humans; Male; Naltrexone; Opioid-Related Disorders; Treatment Outcome; Young Adult | 2016 |
The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation.
Topics: Administration, Cutaneous; Adult; Combined Modality Therapy; Counseling; Depression; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Personality Inventory; Smoking Cessation; Treatment Outcome | 2008 |
Course of late-life depression with alcoholism following combination therapy.
Topics: Aging; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Middle Aged; Naltrexone; Placebos; Sertraline; Severity of Illness Index; Treatment Outcome | 2009 |
Challenges to antagonist blockade during sustained-release naltrexone treatment.
Topics: Adult; Crime; Delayed-Action Preparations; Depression; Drug Implants; Drug Overdose; Euphoria; Female; Hair; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Patient Compliance; Psychiatric Status Rating Scales; Secondary Prevention; Substance Abuse Detection; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2010 |
The association between naltrexone treatment and symptoms of depression in opioid-dependent patients.
Topics: Adult; Affect; Depression; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2011 |
Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Anxiety Disorders; Depression; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotics; Predictive Value of Tests; Prospective Studies; Secondary Prevention; Somatoform Disorders; Surveys and Questionnaires; Taurine; Treatment Outcome | 2005 |
Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence.
Topics: Adult; Depression; Female; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists | 2006 |
Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.
Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Alcoholism; Attitude; Body Mass Index; Bulimia; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Feeding and Eating Disorders; Female; gamma-Glutamyltransferase; Humans; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Treatment Outcome | 2007 |
Anger management style and endogenous opioid function: is gender a moderator?
Topics: Adult; Anger; Anxiety; Depression; Double-Blind Method; Electric Stimulation; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Nociceptors; Opioid Peptides; Pain Threshold; Sex Factors; Skin; Statistics as Topic | 2007 |
A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.
Topics: Alcoholism; Body Weight; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Naltrexone; Narcotic Antagonists; Patient Admission; Pilot Projects; Treatment Outcome | 1994 |
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Taurine; Treatment Outcome | 2001 |
35 other study(ies) available for naltrexone and Depression
Article | Year |
---|---|
Trajectories of depression among patients in treatment for opioid use disorder: A growth mixture model secondary analysis of the XBOT trial.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Depression; Humans; Naltrexone; Opioid-Related Disorders | 2023 |
Chronic administration of buprenorphine in combination with samidorphan produces sustained effects in olfactory bulbectomised rats and Wistar-Kyoto rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Buprenorphine; Depression; Disease Models, Animal; Drug Therapy, Combination; Locomotion; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley | 2019 |
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression.
Topics: Animals; Behavior Observation Techniques; Behavior, Animal; Depression; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Repositioning; Female; Humans; Male; Mice; Mice, Knockout; Naltrexone; Nucleus Accumbens; Receptors, Opioid, kappa; Receptors, Opioid, mu; Sex Factors | 2020 |
Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Hindlimb Suspension; Ketamine; Locomotion; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Psychomotor Agitation; Receptors, Opioid | 2021 |
Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cell Proliferation; Depression; Depressive Disorder; Disease Models, Animal; Hippocampus; Interferon-alpha; Male; Naltrexone; Narcotic Antagonists; Neurons; Rats, Wistar; Receptors, Opioid | 2018 |
Opioid system contribution to the antidepressant-like action of m-trifluoromethyl-diphenyl diselenide in mice: A compound devoid of tolerance and withdrawal syndrome.
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder; Male; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Organosilicon Compounds; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Swimming | 2017 |
Lack of Opioid System in the Antidepressant Actions of Ketamine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Ketamine; Lipopolysaccharides; Male; Mice; Naltrexone; Stress, Psychological | 2019 |
Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats.
Topics: Amygdala; Animals; Behavior, Animal; Buprenorphine; Depression; Hippocampus; Male; Motor Activity; Naltrexone; Nociceptin; Opioid Peptides; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Receptors, Opioid, mu; RNA, Messenger; Swimming | 2019 |
Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect-Reply.
Topics: Alcoholism; Antidepressive Agents; Depression; Humans; Ketamine; Naltrexone; Receptors, Opioid | 2019 |
Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect.
Topics: Alcoholism; Antidepressive Agents; Depression; Humans; Ketamine; Naltrexone; Receptors, Opioid | 2019 |
Resistance to depression through interference of opioid and nitrergic systems in bile-duct ligated mice.
Topics: Animals; Bile Ducts; Cholestasis; Depression; Enzyme Inhibitors; Ligation; Male; Mice; Motor Activity; Naltrexone; Narcotic Antagonists; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Swimming | 2013 |
Pain-related depression of the mesolimbic dopamine system in rats: expression, blockade by analgesics, and role of endogenous κ-opioids.
Topics: Analgesics, Opioid; Animals; Benzeneacetamides; Depression; Disease Models, Animal; Dopamine; Gene Expression Regulation; Ketoprofen; Lactic Acid; Male; Medial Forebrain Bundle; Morphine; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Pain; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Self Stimulation; Time Factors | 2014 |
Opioid/NMDA receptors blockade reverses the depressant-like behavior of foot shock stress in the mouse forced swimming test.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Depression; Dizocilpine Maleate; Electroshock; Foot; Male; Mice; Morphine; Motor Activity; N-Methylaspartate; Naltrexone; Narcotic Antagonists; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Stress, Psychological; Swimming | 2014 |
Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Buprenorphine; Depression; Desipramine; Dopamine; Male; Mice; Mice, Inbred C57BL; Motor Activity; Naltrexone; Narcotics; Nucleus Accumbens; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Swimming | 2015 |
Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients.
Topics: Adult; Anhedonia; Corpus Striatum; Delayed-Action Preparations; Depression; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Plasma Membrane Transport Proteins; Female; Heroin Dependence; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neuropsychological Tests; Positron-Emission Tomography; Psychiatric Status Rating Scales; Radiopharmaceuticals; Substance Abuse Detection; Tomography, Emission-Computed, Single-Photon; Tropanes | 2015 |
Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice.
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Buprenorphine; Depression; Disease Models, Animal; Drug Therapy, Combination; Male; Maze Learning; Mice; Naltrexone; Narcotic Antagonists; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2015 |
Endogenous opioids regulate glucocorticoid-dependent stress-coping strategies in mice.
Topics: Adaptation, Psychological; Amygdala; Animals; Anxiety; Conditioning, Psychological; Depression; Dexamethasone; Fear; Freezing Reaction, Cataleptic; Glucocorticoids; Male; Mice, Inbred Strains; Mifepristone; Motor Activity; Naltrexone; Neurotransmitter Agents; Opioid Peptides; Receptors, Glucocorticoid; Receptors, Opioid; Species Specificity; Stress, Psychological | 2016 |
Correspondence of Interactive Voice Response (IVR) reports of nicotine withdrawal, craving, and negative mood with questionnaire ratings.
Topics: Adult; Comorbidity; Depression; Female; Humans; Irritable Mood; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Self Disclosure; Self-Assessment; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires | 2008 |
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
Topics: Adolescent; Adult; Aged; Depression; Disabled Persons; Fatigue; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Naltrexone; Pilot Projects; Polymorphism, Single Nucleotide; Receptors, Opioid, mu; RNA, Messenger | 2008 |
Alleviation of both binge eating and sexual dysfunction with naltrexone.
Topics: Alcoholism; Antidepressive Agents; Bulimia; Child; Child Abuse; Depression; Female; Heroin Dependence; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors; Sex Work; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Stress Disorders, Post-Traumatic | 2008 |
Treating depression along with alcohol dependence.
Topics: Alcohol-Related Disorders; Depression; Health Knowledge, Attitudes, Practice; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2010 |
The novel δ opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions.
Topics: Analgesics; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Benzamides; Depression; Dopamine Antagonists; Imipramine; Male; Mice; Mice, Inbred ICR; Morphinans; Motor Activity; Naltrexone; Narcotic Antagonists; Pain Measurement; Piperazines; Receptors, Opioid, delta; Seizures; Swimming | 2011 |
Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats.
Topics: Analysis of Variance; Animals; Cocaine; Conditioning, Operant; Depression; Disease Models, Animal; Dopamine Uptake Inhibitors; Drug Administration Routes; Immobility Response, Tonic; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Opioid, kappa; Reinforcement Schedule; Self Administration; Substance Withdrawal Syndrome; Swimming; Time Factors | 2012 |
[Differences in depression severity and frequency of relapses in opiate addicts treated with methadone or opiate blocker after detoxification].
Topics: Adult; Depression; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Young Adult | 2012 |
Centrally administered apelin-13 induces depression-like behavior in mice.
Topics: Amino Acid Sequence; Animals; Apelin Receptors; Corticotropin-Releasing Hormone; Depression; Injections; Injections, Intraventricular; Intercellular Signaling Peptides and Proteins; Male; Mice; Motor Activity; Naloxone; Naltrexone; Peptide Fragments; Receptor, Angiotensin, Type 1; Receptors, Corticotropin-Releasing Hormone; Receptors, G-Protein-Coupled; Receptors, Opioid, kappa; Rotarod Performance Test; Single-Blind Method | 2012 |
In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor.
Topics: Analgesics; Animals; Anxiety; Behavior, Animal; Depression; Guinea Pigs; Ligands; Male; Mice; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2013 |
Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cyclic AMP Response Element-Binding Protein; Depression; Dynorphins; Enkephalins; Helplessness, Learned; Immunohistochemistry; Male; Mice; Mice, Transgenic; Mutation; Naltrexone; Nucleus Accumbens; Prosencephalon; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa | 2002 |
Pharmacological management of a teen with significant alcohol use and depression.
Topics: Adolescent; Alcoholism; Antidepressive Agents; Depression; Female; Humans; Naltrexone; Narcotic Antagonists; Sertraline | 2006 |
Negative affect, pain and sex: the role of endogenous opioids.
Topics: Adolescent; Adult; Affect; Anger; Anxiety; Central Nervous System; Cold Temperature; Depression; Double-Blind Method; Electroshock; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Neuropsychological Tests; Opioid Peptides; Pain; Pain Measurement; Pain Threshold; Physical Stimulation; Sex Characteristics; Stress, Psychological | 2007 |
The behavioural depression of hippocampal kindled rats is attenuated by subcutaneous and intracerebroventricular naltrexone.
Topics: Amygdala; Animals; Depression; Humans; Injections, Intraventricular; Injections, Subcutaneous; Kindling, Neurologic; Male; Naloxone; Naltrexone; Rats; Rats, Inbred Strains | 1984 |
Rhabdomyolysis associated with naltrexone.
Topics: Adult; Alcoholism; Depression; Humans; Male; Naltrexone; Narcotic Antagonists; Rhabdomyolysis | 1999 |
Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses.
Topics: Animals; Anxiety; Binding Sites; Darkness; Depression; Electroshock; Female; Gene Deletion; Light; Male; Mice; Mice, Knockout; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Pain Threshold; Phenotype; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Sex Characteristics; Swimming | 2000 |
Early exposure to chronic variable stress facilitates the occurrence of anhedonia and enhanced emotional reactions to novel stressors: reversal by naltrexone pretreatment.
Topics: Animals; Avoidance Learning; Behavior, Animal; Chronic Disease; Conditioning, Psychological; Depression; Disease Models, Animal; Fear; Feeding Behavior; Male; Maze Learning; Naltrexone; Narcotic Antagonists; Opioid Peptides; Random Allocation; Rats; Rats, Wistar; Single-Blind Method; Stress, Psychological | 2000 |
[Naltrexone in the treatment of dissociative disorders--reflections with regard to a comprehensive therapeutic concept of borderline disorders].
Topics: Adult; Borderline Personality Disorder; Combined Modality Therapy; Depression; Dissociative Disorders; Female; Humans; Naltrexone; Narcotic Antagonists; Psychotherapeutic Processes; Psychotherapy; Self-Injurious Behavior; Stress Disorders, Post-Traumatic; Treatment Outcome | 2001 |
The clinical usefulness of narcotic antagonists: preliminary findings on the use of naltrexone.
Topics: Adult; Alcoholism; Boston; Cannabis; Depression; Emotions; Follow-Up Studies; Heroin Dependence; Humans; Internal-External Control; Male; Naloxone; Naltrexone; Patient Acceptance of Health Care; Patient Dropouts; Psychotherapy; Self Concept; Sleep | 1975 |